Salarius Pharmaceuticals Presents SP-3164 Preclinical Data
Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-01-27, 20:39
